What BMI cut-off applies to Mounjaro in the UK?

Does the BMI cut-off change depending on how you're accessing Mounjaro?

Yes, and this is where a lot of confusion starts. There are effectively two sets of BMI thresholds in play in the UK, and they serve different purposes.

For a private prescription, the relevant figure comes from Mounjaro's product licence. The medicine is authorised for adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present. Those conditions include type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea and osteoarthritis, among others. What counts as a qualifying BMI for Mounjaro covers the full list if you want to check your specific situation.

For NHS access, the bar is higher. NICE's appraisal of tirzepatide (published as TA1026 in December 2024) recommends it for adults with a BMI of 35 or above plus at least one weight-related comorbidity, within a specialist weight management service. The NHS is rolling out access in phases, and not everyone who qualifies on paper will have a service available to them yet.

The private and NHS routes are genuinely separate. Meeting the licensed threshold for private prescribing doesn't automatically translate into NHS eligibility, and the reverse is also true.

What if your BMI sits between 27 and 29.9, does the condition requirement make a real difference?

It does, and it's worth being specific about this. A BMI of 27 to 29.9 on its own is not sufficient for a Mounjaro prescription under the current licence. A documented weight-related health condition has to be present alongside it. The conditions that qualify are the same ones listed above, pre-existing diagnoses, not symptoms you've noticed but haven't had investigated.

If your BMI is in this range and you're unsure whether a condition you have qualifies, the right step is a clinical consultation. A prescriber can review your medical history and confirm whether your situation meets the threshold. Treatment eligibility at a BMI of 27 goes into more detail on how this range is assessed in practice.

One thing worth knowing: the 27-threshold cases often receive closer scrutiny at clinical review, precisely because the medicine isn't licensed for general weight management at that BMI, it's licensed for weight management in the context of an existing health risk. That's not a barrier for people who genuinely qualify; it's the clinical framework working as it should.

Do ethnic background adjustments apply to the Mounjaro BMI cut-off?

They do. UK clinical guidance recognises that for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the metabolic risks associated with excess weight tend to appear at a lower BMI than in white European populations. As a result, the thresholds used in NICE's recommendation are set 2.5 kg/m² lower for these groups.

In practical terms: where the standard private licence threshold is 30, a lower figure may apply; where NICE sets 35 for NHS access, the equivalent is 32.5 for eligible ethnic backgrounds. If you are wondering whether a BMI of 25 could qualify you for Mounjaro given an ethnic background adjustment, the answer depends on which conditions are present alongside it. The NHS BMI calculator prompts you to include ethnic background in its assessment for exactly this reason.

This adjustment is easy to overlook when people are checking the headline numbers online. If it applies to you, it can make a meaningful difference to whether you fall above or below the threshold, which is one reason the consultation process matters more than a single number. For context on how pricing relates to eligibility decisions, the background on Mounjaro's UK cost explains what changed from September 2025 onward.

Is BMI the only thing that determines whether treatment goes ahead?

No. BMI qualifies you for consideration; it doesn't determine suitability on its own. A prescriber also reviews your medical history, any medicines you're currently taking, relevant contraindications and your overall health picture before a prescription is issued.

Some situations require extra care regardless of BMI. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, or certain gastrointestinal conditions are examples where a prescriber would want to explore further, or where Mounjaro may not be appropriate at all. Interactions with other supplements is one example of the kind of question that comes up during a thorough clinical review.

People who want to pause or adjust treatment also go through a review process. Taking a break from Mounjaro is something that should always be discussed with your prescriber rather than decided unilaterally.

At nume, every application is reviewed personally by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. If you'd like to see whether you meet the BMI and clinical criteria, check your eligibility with a free consultation.